相关实验视频

Updated: Feb 17, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

在HHCC的TACE组合中,Sintilimab Plus IBI305和PD-1抑制剂加TKI之间的疗效和安全性比较

Houxiang Ya¹, Kai Wang², Huixia Qin³

¹Department of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Province, China.

Liver international : official journal of the International Association for the Study of the Liver

|February 16, 2026

概括

与TACE结合的sintilimab和bevacizumab生物类似剂显示出与PD-1抑制剂和TKI治疗方案相似的疗效和安全性,用于不可切除的肝细胞癌 (uHCC). 辛提利马布治疗方案为患有大型瘤,孤独病变或门静脉瘤血栓症的患者提供了更大的生存益处.

科学领域:

肝胆瘤学肝胆瘤学
癌症免疫疗法癌症免疫疗法
干预性瘤学干预性瘤学

背景情况:

无法切除的肝细胞癌 (uHCC) 管理依赖于系统治疗与透管动脉化学栓塞 (TACE) 结合.
对于HHCC中不同组合治疗方案的有限的直接比较研究存在.
这项研究比较了sintilimab和bevacizumab生物类似剂 (IBI305) 与PD-1抑制剂和氨酸激酶抑制剂 (TKI) 结合TACE治疗HHCC.

研究的目的:

为了比较两种组合治疗方案对HHCC的疗效和安全性.
评估整体生存率 (OS),无进展生存率 (PFS),客观反应率 (ORR) 和疾病控制率 (DCR).
在HHCC患者中评估与治疗相关的不良事件 (TRAE).

主要方法:

对225名hhCC患者进行了回顾性研究.
在TACE加Sintilimab/bevacizumab生物类似物 (TSB组) 和TACE加PD-1抑制剂/TKI (TTP组) 之间进行比较.
使用倾向性得分匹配 (PSM) 来最大限度地减少偏差,然后对OS,PFS,ORR,DCR和TRAE进行分析.

主要成果:

在PSM后,136名患者 (每组68人) 在TSB和TTP组之间在OS或PFS中没有显著差异.
目标反应率 (ORR) 和疾病控制率 (DCR) 通过RECIST1.1和mRECIST标准在组之间是可比的.
亚组分析表明,TSB疗法对患有大型瘤,孤独病变或门静脉瘤血栓的患者有更高的生存益处,而TTP疗法对多焦点瘤更有益.

结论:

TSB 和 TTP 方案在 uHCC 治疗中表现出可比的疗效和安全性.
在特定的HHCC患者小组中,TSB疗法显示了增强生存效益的潜力.
进一步的研究可能会阐明每个综合治疗方案的最佳患者选择.

关键词:

卡普兰梅耶尔方法组合疗法治疗组合治疗.免疫检查点抑制剂免疫检查点抑制剂分子向疗法是指分子向疗法.总体存活率总体存活率没有进展的生存率.倾向性得分匹配的比分匹配在安全方面,安全是安全的.通过动脉的化学栓塞.不能切除的肝细胞细胞.

更多相关视频

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...